2023
Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)
Kewan T, Bewersdorf J, Blaha O, Stahl M, Al Ali N, DeZern A, Sekeres M, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, Amaya M, Zeidner J, Savona M, Stempel J, Chandhok N, Logothetis C, Ramaswamy R, Rose A, Roboz G, Rolles B, Wang E, Harris A, Shallis R, Xie Z, Padron E, Maciejewski J, Sallman D, Della Porta M, Komrokji R, Zeidan A. Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA). Blood 2023, 142: 3240. DOI: 10.1182/blood-2023-186340.Peer-Reviewed Original ResearchComplete remission rateOverall response rateOutcome of ptsMedian overall survivalOverall survivalHypomethylating agentHMA initiationHR-MDSC-indexRisk groupsScoring systemInternational Prognostic Scoring SystemResponse criteriaPrognostic scoring systemHigh-risk diseaseLarge multicenter cohortHigh-risk groupHarrell's C-indexLog-rank testPrediction of outcomeDifferent scoring systemsSubsequent validation studiesHMA cyclesMedian followAllogeneic HSCTTreatment Patterns Among Patients with Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia after Intensive Induction Chemotherapy
Rojek A, McCormick B, Cwykiel J, Odetola O, Abaza Y, Achar R, Shallis R, Bradshaw D, Standridge M, Kota V, Badar T, Patel A. Treatment Patterns Among Patients with Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia after Intensive Induction Chemotherapy. Blood 2023, 142: 1484. DOI: 10.1182/blood-2023-185163.Peer-Reviewed Original ResearchCore-binding factor acute myeloid leukemiaFactor acute myeloid leukemiaIntensive induction chemotherapyOutcome of ptsInitial complete remissionLine therapyComplete remissionLong-term outcomesAcute myeloid leukemiaCBF-AMLPolymerase chain reactionR diseaseInduction chemotherapyMedian OSFirst relapseIntensive inductionInitial diagnosisMyeloid leukemiaMolecular testingNext-generation sequencingKIT inhibitorsMulti-center retrospective studyMeasurable residual disease testingAnthracycline-based inductionEuropean LeukemiaNet guidelinesOutcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies
Patel A, Yoon J, Johnston H, Davidson M, Viswabandya A, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Dean R, Kassner J, Rampal R, Murthy S, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Cursio J, Odenike O. Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies. Blood 2023, 142: 3192. DOI: 10.1182/blood-2023-174790.Peer-Reviewed Original ResearchMedian overall survivalMorphologic leukemia-free stateAllo-HCTOutcome of ptsStem cell transplantIntensive chemotherapyBlast phaseBP diagnosisComplete responseChronic-phase myeloproliferative neoplasmsMyeloproliferative neoplasmsJAK inhibitorsPartial responseTreatment failureUnrelated donorsLonger median overall survivalMulti-center retrospective analysisAllogeneic stem cell transplantHematopoietic stem cell transplantMethods Retrospective chart reviewComparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy
Badar T, Atallah E, Shallis R, Patel A, De Camargo Correia G, Goldberg A, Saliba A, Bewersdorf J, Duvall A, Bradshaw D, Abaza Y, Murthy S, Palmisiano N, Kota V, Litzow M. Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy. Blood 2023, 142: 592. DOI: 10.1182/blood-2023-184626.Peer-Reviewed Original ResearchAcute myeloid leukemiaComplete remission rateOverall survivalDuration of responseMultivariable analysisComplex cytogeneticsAllo-HCTRemission rateMyeloid leukemiaAllogeneic stem cell transplantSecondary acute myeloid leukemiaAdverse-risk diseaseCR/CRiMedian overall survivalOutcome of ptsResults Baseline characteristicsKaplan-Meier methodMore effective treatment strategiesSignificant univariate predictorsStem cell transplantEffective treatment strategiesReal-world studyLogistic regression modelsMedian followVEN group
2022
The Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting.
Riaz F, Zhu H, Cheng W, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Parikh R, Reuss J, Prsic E, Doroshow D. The Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.28_suppl.300.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsRetrospective studyInpatient settingOutcome studiesPT outcomesStage IV solid malignancyYale-New Haven HospitalImaging-based responseMedian prior linesNon-curative intentOutcome of ptsCTLA-4 inhibitorsMulticenter retrospective studyPD-L1 expressionPoor clinical outcomeCare of patientsTime of administrationMount Sinai HospitalGeorgetown University HospitalHealth care systemICI administrationICI doseICI initiation
2017
KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Machiels J, Licitra L, Rischin D, Waldron J, Burtness B, Gregoire V, Shekar T, Brown H, Cheng J, Siu L. KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Journal Of Clinical Oncology 2017, 35: tps6090-tps6090. DOI: 10.1200/jco.2017.35.15_suppl.tps6090.Peer-Reviewed Original ResearchBlinded independent central reviewConcomitant chemoradiotherapyRECIST v1.1LA-HNSCCP16-positive oropharyngeal cancerPrimary efficacy end pointRecurrent/metastatic HNSCCNeck squamous cell carcinomaDefinitive concomitant chemoradiotherapyECOG PS 0Efficacy end pointOutcome of ptsP16 negative HNSCCEvent-free survivalHalf of patientsSquamous cell carcinomaEnd of treatmentIndependent central reviewQuality of lifeMeasurable diseaseAdvanced diseaseCTCAE v4.0Primary surgeryAdvanced headNeck dissection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply